drugset / Trial / NCT00855738

A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice

NCT00855738

Phase 4 Completed 111 enrolled Viatris Inc.
NaSingle-groupOpen-labelTreatment

Summary

Assessment of the efficacy under daily clinical conditions of the new antiepileptic drugs (AEDs) gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine and topiramate, used as first-choice combination therapy (bitherapy) in patients with focal epilepsy.

Timeline

Start
2007-05
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Gabapentin Small molecule 3600 mg
Subject Lamotrigine Small molecule 400 mg
Subject Levetiracetam Other / unclassified 3000 mg
Subject Oxcarbazepine Small molecule 2400 mg
Subject Pregabalin Small molecule 600 mg
Subject Tiagabine Small molecule 30 mg
Subject Topiramate Small molecule 400 mg
Subject Zonisamide Other / unclassified 500 mg

Indications